State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China; Department of Pharmacy, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Science and Education Division, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
J Ethnopharmacol. 2019 Oct 28;243:112093. doi: 10.1016/j.jep.2019.112093. Epub 2019 Jul 17.
Ginseng (Panax ginseng C. A. Mey) has been widely used in Asian countries for thousands of years. It has auxiliary anticancer efficacy and its derived preparations (e.g. Shenmai injection) are prescribed for cancer patients as Traditional Chinese Medicines clinically in China.
The involved adjuvant anticancer mechanisms of ginseng are still unknown. The present study evaluated the anti-cancer effect of total ginsenosides extract (TGS) and determined the anticancer mechanisms of TGS-induced cell death in human non-small cell lung cancer (NSCLC) cells.
The anti-cancer effect of TGS was evaluated in NSCLC by cell proliferation assay. The autophagy flux induction of TGS were tested and validated by Western blot, immunofluorescence and transmission electron microscope. The mechanisms of TGS in inducing autophagic cell death were validated by Western blot, gene knockdown and quantitative real time PCR assay.
We found TGS could induce cell death in concentration and time dependent manners, and the cell morphology of NSCLC changed from cobblestone shape to elongated spindle shape after treated with TGS. In the study of cell autophagy, we confirm that TGS could upregulate autophagy flux and induce autophagic cell death through activation endoplasmic reticulum stress. Further investigations demonstrated this process was mediated by the ATF4-CHOP-AKT1-mTOR axis in NSCLC cells.
Our findings suggested that TGS could induce autophagic cell death in NSCLC cells through activation of endoplasmic reticulum stress, disclosing another characteristic of TGS-induced cell death and a novel mechanism of TGS and its derived preparations in clinical treatment of cancer patients.
人参(Panax ginseng C. A. Mey)在亚洲国家被广泛应用已有数千年的历史。它具有辅助抗癌功效,其衍生制剂(如参麦注射液)在中国临床上被开给癌症患者作为中药使用。
人参的辅助抗癌机制尚不清楚。本研究评估了总人参皂苷提取物(TGS)的抗癌作用,并确定了 TGS 在人非小细胞肺癌(NSCLC)细胞中诱导细胞死亡的抗癌机制。
通过细胞增殖测定评估 TGS 在 NSCLC 中的抗癌作用。通过 Western blot、免疫荧光和透射电子显微镜测试和验证 TGS 诱导的自噬通量。通过 Western blot、基因敲低和实时定量 PCR 测定验证 TGS 诱导自噬细胞死亡的机制。
我们发现 TGS 可以浓度和时间依赖的方式诱导细胞死亡,并且 TGS 处理后 NSCLC 细胞的形态从鹅卵石形状变为细长的纺锤形。在细胞自噬研究中,我们证实 TGS 可以通过激活内质网应激来上调自噬通量并诱导自噬性细胞死亡。进一步的研究表明,这个过程是由 NSCLC 细胞中的 ATF4-CHOP-AKT1-mTOR 轴介导的。
我们的研究结果表明,TGS 可以通过激活内质网应激诱导 NSCLC 细胞发生自噬性细胞死亡,揭示了 TGS 诱导细胞死亡的另一个特征,以及 TGS 及其衍生制剂在癌症患者临床治疗中的一个新机制。